Showing results (461-470 of 554) with videos related to

Sort By:
Pageof 56
Frontiers in Big Data|July 2, 2021
Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection TrialsWilliam Chad Young, Lindsay N Carpp, Sidhartha Chaudhury, et al.
Biorxiv : the Preprint Server for Biology|April 6, 2021
Sexually dimorphic placental responses to maternal SARS-CoV-2 infectionEvan A Bordt, Lydia L Shook, Caroline Atyeo, et al.
JAMA|May 13, 2021
Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating WomenAi-Ris Y Collier, Katherine McMahan, Jingyou Yu, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|October 10, 2024
Measurement of circulating viral antigens post-SARS-CoV-2 infection in a multicohort studyZoe Swank, Ella Borberg, Yulu Chen, et al.
Pharmaceutics|May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIVBryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Science Translational Medicine|September 8, 2017
Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challengeBoris Julg, Lawrence J Tartaglia, Brandon F Keele, et al.
Plos Pathogens|April 29, 2020
Correction: ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Plos Pathogens|December 4, 2019
ALVAC-HIV B/C candidate HIV vaccine efficacy dependent on neutralization profile of challenge virus and adjuvant dose and typeLuca Schifanella, Susan W Barnett, Massimiliano Bissa, et al.
Nature Communications|October 31, 2020
SARS-CoV-2 viral load is associated with increased disease severity and mortalityJesse Fajnzylber, James Regan, Kendyll Coxen, et al.
NPJ Vaccines|May 23, 2024
Immunogenicity of 2 therapeutic mosaic HIV-1 vaccine strategies in individuals with HIV-1 on antiretroviral therapyBoris Julg, Kathryn E Stephenson, Frank Tomaka, et al.
Pageof 56